MediciNova Stock Price, News & Analysis (NASDAQ:MNOV)

$10.61 -0.40 (-3.63 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$10.61
Today's Range$10.61 - $10.99
52-Week Range$4.40 - $11.45
Volume218,000 shs
Average Volume304,582 shs
Market Capitalization$450.62 million
P/E RatioN/A
Dividend YieldN/A
Beta0.38

About MediciNova (NASDAQ:MNOV)

MediciNova logoMedicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Debt-to-Equity RatioN/A
Current Ratio9.83%
Quick Ratio9.83%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.94 per share
Price / Book11.29

Profitability

Trailing EPS($0.32)
Net Income$-11,160,000.00
Net MarginsN/A
Return on Equity-32.09%
Return on Assets-28.09%

Miscellaneous

Employees9
Outstanding Shares40,930,000

MediciNova (NASDAQ:MNOV) Frequently Asked Questions

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) released its earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.

Who are some of MediciNova's key competitors?

Who are MediciNova's key executives?

MediciNova's management team includes the folowing people:

  • Jeffrey Himawan Ph.D., Independent Chairman of the Board (Age 53)
  • Yuichi Iwaki M.D., Ph.D., President, Chief Executive Officer, Director (Age 65)
  • Ryan Selhorn, Chief Financial Officer
  • Geoffrey G. O'Brien J.D., Vice President (Age 46)
  • Masatsune Okajima, Vice President, Head - Japanese Office (Age 47)
  • Kazuko Matsuda M.D., Ph.D., Chief Medical Officer (Age 48)
  • Hideki Nagao, Director (Age 61)
  • Yoshio Ishizaka, Independent Director (Age 75)
  • Yutaka Kobayashi, Independent Director (Age 51)

Who owns MediciNova stock?

MediciNova's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.74%), Geode Capital Management LLC (0.58%), Bank of New York Mellon Corp (0.30%), Renaissance Technologies LLC (0.20%), Deutsche Bank AG (0.20%) and Schwab Charles Investment Management Inc. (0.16%). Company insiders that own MediciNova stock include Geoffrey Obrien, Yoshio Ishizaka and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova.

Who sold MediciNova stock? Who is selling MediciNova stock?

MediciNova's stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp and Rhumbline Advisers. View Insider Buying and Selling for MediciNova.

Who bought MediciNova stock? Who is buying MediciNova stock?

MediciNova's stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Renaissance Technologies LLC, Alps Advisors Inc., Paloma Partners Management Co, The Manufacturers Life Insurance Company , Wells Fargo & Company MN, Schwab Charles Investment Management Inc. and Geode Capital Management LLC. Company insiders that have bought MediciNova stock in the last two years include Yoshio Ishizaka and Yutaka Kobayashi. View Insider Buying and Selling for MediciNova.

How do I buy MediciNova stock?

Shares of MediciNova can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MediciNova's stock price today?

One share of MediciNova stock can currently be purchased for approximately $10.61.

How big of a company is MediciNova?

MediciNova has a market capitalization of $450.62 million. The biopharmaceutical company earns $-11,160,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. MediciNova employs 9 workers across the globe.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


MarketBeat Community Rating for MediciNova (MNOV)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  113
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MediciNova (NASDAQ:MNOV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

MediciNova (NASDAQ:MNOV) Consensus Price Target History

Price Target History for MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ:MNOV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2017Credit Suisse GroupInitiated CoverageOutperform -> OutperformHighView Rating Details
3/21/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$6.00 -> $11.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

MediciNova (NASDAQ:MNOV) Earnings History and Estimates Chart

Earnings by Quarter for MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ MNOV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/23/2017Q3 2017($0.09)($0.11)ViewN/AView Earnings Details
7/26/2017Q2 2017($0.10)($0.08)ViewN/AView Earnings Details
4/26/2017Q1 2017($0.10)($0.09)ViewN/AView Earnings Details
2/14/2017Q4 2016($0.04)ViewN/AView Earnings Details
10/25/2016Q3 2016($0.05)($0.08)ViewN/AView Earnings Details
7/26/2016Q2 2016($0.10)ViewN/AView Earnings Details
4/27/2016Q1 2016($0.08)($0.11)ViewN/AView Earnings Details
2/25/2016Q4 2015($0.09)ViewN/AView Earnings Details
10/29/2015Q3 2015($0.10)($0.06)ViewN/AView Earnings Details
7/30/2015Q2 2015($0.10)($0.09)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.10)($0.09)ViewN/AView Earnings Details
11/7/2013Q3 2013($0.10)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.14)$0.37 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.13)($0.14)$0.31 millionViewN/AView Earnings Details
3/28/2013Q4 2012($0.12)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.14)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.26)($0.14)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.28)($0.24)ViewN/AView Earnings Details
3/29/2012Q4 2011($0.20)($0.22)ViewN/AView Earnings Details
11/15/2011Q3 2011($0.28)($0.25)ViewN/AView Earnings Details
8/16/2011Q2 2011($0.34)($0.31)ViewN/AView Earnings Details
5/17/2011Q1 2011($0.38)($0.45)ViewN/AView Earnings Details
3/31/2011Q4 2010($0.40)($0.40)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.42)($0.46)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.39)($0.35)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.41)($0.42)ViewN/AView Earnings Details
3/24/2010Q4 2009($0.40)($0.49)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.46)($0.40)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.39)($0.39)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.26)($0.41)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.12)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.66)($0.40)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.65)($0.33)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.70)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.92)($0.25)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

MediciNova (NASDAQ:MNOV) Earnings Estimates

2018 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.12)($0.12)($0.12)
Q2 20181($0.11)($0.11)($0.11)
Q3 20181($0.11)($0.11)($0.11)
Q4 20181($0.11)($0.11)($0.11)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for MediciNova (NASDAQ:MNOV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MediciNova (NASDAQ MNOV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.20%
Institutional Ownership Percentage: 18.52%
Insider Trades by Quarter for MediciNova (NASDAQ:MNOV)
Institutional Ownership by Quarter for MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ MNOV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/21/2017Yoshio IshizakaDirectorBuy5,000$5.17$25,850.005,000View SEC Filing  
5/15/2017Yutaka KobayashiDirectorBuy1,000$5.60$5,600.0081,800View SEC Filing  
5/12/2017Yutaka KobayashiDirectorBuy24,000$5.62$134,880.0081,800View SEC Filing  
9/15/2016Yutaka KobayashiDirectorBuy11,800$6.44$75,992.0081,800View SEC Filing  
9/9/2016Yutaka KobayashiDirectorBuy10,000$6.67$66,700.0070,000View SEC Filing  
7/5/2016Geoffrey ObrienVPSell3,300$8.00$26,400.008,300View SEC Filing  
12/10/2014Yutaka KobayashiDirectorBuy12,000$3.54$42,480.00View SEC Filing  
11/26/2014Yutaka KobayashiDirectorBuy10,000$3.07$30,700.00View SEC Filing  
11/20/2014Yutaka KobayashiDirectorBuy13,000$3.19$41,470.00View SEC Filing  
11/19/2014Yoshio IshizakaDirectorBuy5,000$2.86$14,300.00View SEC Filing  
9/11/2014Yutaka KobayashiDirectorBuy10,000$2.95$29,500.00View SEC Filing  
9/3/2014Yutaka KobayashiDirectorBuy15,000$2.66$39,900.00View SEC Filing  
12/12/2013Tatsuo IzumiDirectorSell71,270$2.10$149,667.00View SEC Filing  
11/18/2013Tatsuo IzumiDirectorBuy1,270$2.21$2,806.70View SEC Filing  
5/21/2013Arlene MorrisDirectorSell8,800$3.28$28,864.00View SEC Filing  
5/13/2013Tatsuo IzumiDirectorBuy158,730$3.15$499,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MediciNova (NASDAQ MNOV) News Headlines

Source:
DateHeadline
Is MediciNova Inc (NASDAQ:MNOV) A Good Healthcare Bet?Is MediciNova Inc (NASDAQ:MNOV) A Good Healthcare Bet?
finance.yahoo.com - February 22 at 9:28 AM
Zacks Investment Research Comments on MediciNova, Inc.s Q1 2018 Earnings (MNOV)Zacks Investment Research Comments on MediciNova, Inc.'s Q1 2018 Earnings (MNOV)
www.americanbankingnews.com - February 19 at 2:04 AM
MNOV: Raises $40 Million in Underwritten Public OfferingMNOV: Raises $40 Million in Underwritten Public Offering
finance.yahoo.com - February 16 at 4:26 PM
Critical Analysis: MediciNova (MNOV) vs. Its PeersCritical Analysis: MediciNova (MNOV) vs. Its Peers
www.americanbankingnews.com - February 15 at 11:12 PM
MNOV: MN-166 Shows 26% Reduction in Disability Progression in Progressive MS Phase 2 StudyMNOV: MN-166 Shows 26% Reduction in Disability Progression in Progressive MS Phase 2 Study
finance.yahoo.com - February 9 at 9:04 AM
Here's Why MediciNova, Inc. Stock Is Sliding TodayHere's Why MediciNova, Inc. Stock Is Sliding Today
finance.yahoo.com - February 8 at 4:31 PM
Heres Why MediciNova, Inc. Stock Is Sliding TodayHere's Why MediciNova, Inc. Stock Is Sliding Today
www.fool.com - February 8 at 1:42 PM
Medicinova (MNOV) Prices 4.42M Common Share Offering at $9.05/ShMedicinova (MNOV) Prices 4.42M Common Share Offering at $9.05/Sh
www.streetinsider.com - February 8 at 9:03 AM
Zacks: Brokerages Expect MediciNova, Inc. (MNOV) Will Post Earnings of -$0.09 Per ShareZacks: Brokerages Expect MediciNova, Inc. (MNOV) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - February 8 at 1:18 AM
ARRYs COLUMBUS Turns Heads, ZFGN On Course, MNOV UP 66% YTDARRY's COLUMBUS Turns Heads, ZFGN On Course, MNOV UP 66% YTD
www.nasdaq.com - February 7 at 9:03 AM
Active-Investors: Blog Exposure - MediciNovas MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b TrialActive-Investors: Blog Exposure - MediciNova's MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial
www.finanznachrichten.de - February 5 at 8:59 AM
Blog Exposure - MediciNova’s MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b TrialBlog Exposure - MediciNova’s MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial
finance.yahoo.com - February 5 at 8:59 AM
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, CaliforniaMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California
finance.yahoo.com - January 31 at 9:12 AM
MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San DiegoMediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San Diego
finance.yahoo.com - January 31 at 9:12 AM
MediciNova to Present at the 98th Annual Meeting of the Chemical Society of JapanMediciNova to Present at the 98th Annual Meeting of the Chemical Society of Japan
finance.yahoo.com - January 24 at 4:55 PM
MediciNova (MNOV) Rating Lowered to Hold at BidaskClubMediciNova (MNOV) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - January 20 at 9:10 AM
What You Must Know About MediciNova Inc’s (NASDAQ:MNOV) Major InvestorsWhat You Must Know About MediciNova Inc’s (NASDAQ:MNOV) Major Investors
finance.yahoo.com - January 16 at 4:49 PM
Does MediciNova Inc’s (NASDAQ:MNOV) CEO Pay Compared Well With Peers?Does MediciNova Inc’s (NASDAQ:MNOV) CEO Pay Compared Well With Peers?
finance.yahoo.com - January 9 at 10:00 AM
MediciNova Inc (NASDAQ:MNOV): What’s The Analyst Consensus Outlook?MediciNova Inc (NASDAQ:MNOV): What’s The Analyst Consensus Outlook?
finance.yahoo.com - January 2 at 9:57 AM
Does MediciNova Inc’s (NASDAQ:MNOV) Past Performance Indicate A Stronger Future?Does MediciNova Inc’s (NASDAQ:MNOV) Past Performance Indicate A Stronger Future?
finance.yahoo.com - December 23 at 12:55 AM
MNOV: Positive Topline Results for MN-166 in P2 ALS StudyMNOV: Positive Topline Results for MN-166 in P2 ALS Study
finance.yahoo.com - December 13 at 4:59 PM
BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALSBRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS
www.businessinsider.com - December 8 at 4:46 PM
MediciNova stock up more than 50% on positive trial resultsMediciNova stock up more than 50% on positive trial results
finance.yahoo.com - December 8 at 10:02 AM
Is MediciNova Inc (MNOV) Cheap And High Growth?Is MediciNova Inc (MNOV) Cheap And High Growth?
finance.yahoo.com - November 23 at 5:18 PM
MediciNova Appoints Hideki Nagao to its Board of DirectorsMediciNova Appoints Hideki Nagao to its Board of Directors
feeds.benzinga.com - November 10 at 2:55 AM
Is MediciNova Inc (MNOV) Undervalued?Is MediciNova Inc (MNOV) Undervalued?
finance.yahoo.com - November 8 at 8:53 PM
MNOV: Positive Results in Phase 2b Study of MN-166 in Progressive MSMNOV: Positive Results in Phase 2b Study of MN-166 in Progressive MS
finance.yahoo.com - November 1 at 6:21 AM
MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability ProfileMediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile
finance.yahoo.com - October 31 at 6:28 AM
MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability ProfileMediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile
finance.yahoo.com - October 31 at 6:28 AM
Medicinova (MNOV) Reports Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MSMedicinova (MNOV) Reports Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
www.streetinsider.com - October 27 at 8:00 AM
MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and TolerabilityMediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability
finance.yahoo.com - October 27 at 8:00 AM
MediciNova, Upcoming Phase II Data Presentation, Ibudilast ReviewMediciNova, Upcoming Phase II Data Presentation, Ibudilast Review
finance.yahoo.com - October 18 at 7:08 AM
MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine DependenceMediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
finance.yahoo.com - September 20 at 6:23 AM
MediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New YorkMediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New York
finance.yahoo.com - September 18 at 11:02 PM
MediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, FranceMediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, France
finance.yahoo.com - August 30 at 6:42 AM
Insider Buying: MediciNova, Inc. (MNOV) Director Acquires 5,000 Shares of StockInsider Buying: MediciNova, Inc. (MNOV) Director Acquires 5,000 Shares of Stock
www.americanbankingnews.com - August 23 at 4:44 PM
MNOV: MN-166 Shows Activity in Preclinical Brain Cancer StudyMNOV: MN-166 Shows Activity in Preclinical Brain Cancer Study
finance.yahoo.com - August 2 at 5:55 AM
Pre-Open Stock Movers 04/26: (AKBA) (IRTB) (TWTR) Higher; (X) (STX) (CREE) Lower (more...)Pre-Open Stock Movers 04/26: (AKBA) (IRTB) (TWTR) Higher; (X) (STX) (CREE) Lower (more...)
www.streetinsider.com - April 26 at 6:43 PM
Mid-Morning Market Update: Markets Edge Higher; Twitter Earnings Beat ViewsMid-Morning Market Update: Markets Edge Higher; Twitter Earnings Beat Views
www.nasdaq.com - April 26 at 6:43 PM
MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017
www.nasdaq.com - April 10 at 10:25 AM
MediciNovas MN-166: Good Trial, But What About Generic Riluzole?MediciNova's MN-166: Good Trial, But What About Generic Riluzole?
seekingalpha.com - March 29 at 9:43 AM
MEDICINOVA INC Files SEC form 8-K, Regulation FD DisclosureMEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - February 16 at 6:10 PM
MEDICINOVA INC Files SEC form 10-K, Annual ReportMEDICINOVA INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 14 at 8:09 PM
MediciNova Announces MN-166 (ibudilast) ALS...MediciNova Announces MN-166 (ibudilast) ALS...
www.benzinga.com - February 8 at 1:14 AM
Leading addiction researchers discuss MN-166 in symposium on novel pharmacotherapies to treat substance use disordersLeading addiction researchers discuss MN-166 in symposium on novel pharmacotherapies to treat substance use disorders
www.nasdaq.com - February 6 at 6:41 PM
Medicinova (MNOV) Positive MN-166 Data Published in NeuropsychopharmacologyMedicinova (MNOV) Positive MN-166 Data Published in Neuropsychopharmacology
www.streetinsider.com - January 23 at 6:55 PM
Medicinova (MNOV) Announces EU Orphan Medicinal Product Designation for MN-166Medicinova (MNOV) Announces EU Orphan Medicinal Product Designation for MN-166
www.streetinsider.com - December 21 at 9:40 AM
Medicinova (MNOV) Says Phase 2b Trial of MN-166 in MS Will Continue Following DSMB ReviewMedicinova (MNOV) Says Phase 2b Trial of MN-166 in MS Will Continue Following DSMB Review
www.streetinsider.com - December 20 at 12:30 PM
6:09 am MediciNova announces the phase 2b trial of MN-166 in progressive MS will continue as planned following DSMB review of interim efficacy analysis; expects to receive final data analysis from the study in the 2H176:09 am MediciNova announces the phase 2b trial of MN-166 in progressive MS will continue as planned following DSMB review of interim efficacy analysis; expects to receive final data analysis from the study in the 2H17
us.rd.yahoo.com - December 19 at 10:14 AM
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsMEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - November 10 at 5:56 PM

SEC Filings

MediciNova (NASDAQ:MNOV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MediciNova (NASDAQ:MNOV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MediciNova (NASDAQ MNOV) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.